Tocagen (TOCA) Given a $5.00 Price Target at Leerink Swann
Leerink Swann set a $5.00 price target on Tocagen (NASDAQ:TOCA) in a research report report published on Wednesday, TipRanks reports. The firm currently has a hold rating on the stock.
TOCA has been the topic of several other research reports. Zacks Investment Research upgraded Tocagen from a hold rating to a buy rating and set a $11.00 target price on the stock in a research note on Tuesday, January 29th. Svb Leerink initiated coverage on Tocagen in a report on Monday, April 15th. They issued a market perform rating and a $11.00 price target for the company. ValuEngine downgraded Tocagen from a buy rating to a hold rating in a report on Monday, May 13th. HC Wainwright reissued a buy rating and issued a $14.50 price target on shares of Tocagen in a report on Thursday, May 9th. Finally, Chardan Capital reissued a buy rating on shares of Tocagen in a report on Tuesday, April 23rd. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $16.75.
TOCA opened at $4.59 on Wednesday. Tocagen has a 1 year low of $4.40 and a 1 year high of $15.80. The company has a debt-to-equity ratio of 0.75, a quick ratio of 5.05 and a current ratio of 5.05. The stock has a market capitalization of $209.76 million, a price-to-earnings ratio of -1.88 and a beta of 3.29.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Stratos Wealth Partners LTD. boosted its holdings in Tocagen by 9.0% in the fourth quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock worth $94,000 after acquiring an additional 949 shares in the last quarter. American International Group Inc. boosted its holdings in Tocagen by 11.7% in the first quarter. American International Group Inc. now owns 13,103 shares of the company’s stock worth $142,000 after acquiring an additional 1,368 shares in the last quarter. Beaumont Financial Partners LLC boosted its holdings in Tocagen by 10.4% in the first quarter. Beaumont Financial Partners LLC now owns 14,999 shares of the company’s stock worth $163,000 after acquiring an additional 1,413 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Tocagen by 6.3% in the first quarter. Wells Fargo & Company MN now owns 33,513 shares of the company’s stock worth $364,000 after acquiring an additional 1,980 shares in the last quarter. Finally, Rhumbline Advisers boosted its holdings in Tocagen by 9.4% in the first quarter. Rhumbline Advisers now owns 25,491 shares of the company’s stock worth $277,000 after acquiring an additional 2,188 shares in the last quarter. 33.16% of the stock is owned by institutional investors and hedge funds.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Recommended Story: Is the QQQ ETF safe?
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.